News

Savara Says FDA Likely To Miss Molgramostim Review Deadline

NASDAQ

(RTTNews) - Savara Inc. (SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced on Friday that the U.S. Food and Drug Administration will not meet the November 22, 2026, Prescription Drug User Fee Act target action date for its Biologics

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.